$GH

Kalia Kumud sold $445K of GH

Kalia Kumud (Chief Information Officer) sold 3,418 shares of Guardant Health, Inc. (GH) at $130.24 ($0.45M total) on 2026-06-11.

Original reporting
SEC EDGAR · Kalia Kumud
Published Jun 15, 2026, 10:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may monitor insider activity for sentiment, but the text contains no operational, regulatory, or financial catalyst.

03

What to watch

Insider sales often reflect diversification, taxes, or liquidity needs; the article provides no size-vs-ownership context beyond post-transaction holdings.

Relevance 4/10Novelty 5/10Timing: SEC Form 4 filed 2026-06-15 for a 2026-06-11 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc.

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Guardant Health CIO Kalia Kumud filed an SEC Form 4 selling 3,418 shares at $130.2386 on 2026-06-11.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan stated and no accompanying fundamental catalyst in the text.

Market effects

No sector-level read-across provided; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Because the sale is not explicitly tied to a 10b5-1 plan in the filing text, some traders may treat it as a stronger near-term bearish signal than a typical planned sale.

Key entities

  • Guardant Health, Inc.

    Subject of the SEC Form 4 insider transaction; officer sale disclosed.

  • Kalia Kumud

    Chief Information Officer who sold 3,418 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHigh

Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?

Guardant Health (GH) received FDA approval for its Guardant360 CDx test as a companion diagnostic for AstraZeneca's camizestrant in advanced breast cancer. The company reported Q2 2026 revenue growth of 44% to $335 million, with oncology revenue up 38% and screening revenue up significantly. Despite strong revenue growth, the company reported an adjusted EBITDA loss of $55.9 million and negative free cash flow.

$GHMed

Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer

Guardant360 CDx received EU approval as a companion diagnostic for AstraZeneca's camizestrant in ER-positive, HER2-negative advanced breast cancer. The blood test detects ESR1 mutations, aiding treatment decisions. The approval follows similar nods in the US and Japan, based on the SERENA-6 trial showing improved progression-free survival with camizestrant.